Cargando…

Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection

The effects of casirivimab and imdevimab (C/I) on the innate immune response against SARS-CoV-2 infection remain unclear. We evaluated the effect of C/I on type I interferon (IFN-I) and cytokines in patients with SARS-CoV-2 infection. This prospective observational study recruited consecutive patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagaoka, Kentaro, Kawasuji, Hitoshi, Takegoshi, Yusuke, Murai, Yushi, Kaneda, Makito, Ueno, Akitoshi, Miyajima, Yuki, Niimi, Hideki, Morinaga, Yoshitomo, Yamamoto, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318908/ https://www.ncbi.nlm.nih.gov/pubmed/35891380 http://dx.doi.org/10.3390/v14071399

Ejemplares similares

Circulating Type I Interferon Levels in the Early Phase of COVID-19 Are Associated With the Development of Respiratory Failure
por: Nagaoka, Kentaro, et al.
Publicado: (2022)

Dominant CT Patterns and Immune Responses during the Early Infection Phases of Different SARS-CoV-2 Variants
por: Nagaoka, Kentaro, et al.
Publicado: (2023)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity
por: Kawasuji, Hitoshi, et al.
Publicado: (2021)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

High Incidence of Metastatic Infections in Panton-Valentine Leucocidin-Negative, Community-Acquired Methicillin-Resistant Staphylococcus aureus Bacteremia: An 11-Year Retrospective Study in Japan
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test
por: Murai, Yushi, et al.
Publicado: (2021)

Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19
por: Kawasuji, Hitoshi, et al.
Publicado: (2021)

Investigation of nasopharyngeal viral load at discharge in patients with COVID-19
por: Fukui, Yasutaka, et al.
Publicado: (2021)

Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients
por: Kawasuji, Hitoshi, et al.
Publicado: (2020)

Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-Resistant Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021)

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients
por: Kawasuji, Hitoshi, et al.
Publicado: (2021)

Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants
por: Morinaga, Yoshitomo, et al.
Publicado: (2021)

Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022)

Use of Casirivimab and Imdevimab for the Treatment of COVID-19
por: Liu, Ryan, et al.
Publicado: (2022)

Monitoring of viral load by RT-PCR caused decision making to continue ECMO therapy for a patient with COVID-19()
por: Sakamaki, Ippei, et al.
Publicado: (2020)

Casirivimab - Imdevimab in Covid 19 – Early Indian experience
por: Venkitakrishnan, Rajesh, et al.
Publicado: (2022)

Casirivimab/imdevimab: Various toxicities: 2 case reports
Publicado: (2022)

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022)

Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
por: Osugi, Yasuhiro, et al.
Publicado: (2022)

Association of subpleural ground-glass opacities with respiratory failure and RNAemia in COVID-19
por: Nagaoka, K., et al.
Publicado: (2023)

Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
por: Folkman, Rebecca, et al.
Publicado: (2022)

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
por: Jalbert, Jessica J., et al.
Publicado: (2022)

Predictive values of immune indicators on respiratory failure in the early phase of COVID-19 due to Delta and precedent variants
por: Nagaoka, K., et al.
Publicado: (2023)

Prolonged viral clearance of severe acute respiratory syndrome coronavirus 2 in the older aged population
por: Ueno, Akitoshi, et al.
Publicado: (2021)

Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
Publicado: (2022)

PROLONGED COVID-19 INFECTION IN AN IMMUNOSUPPRESSED PATIENT TREATED WITH CASIRIVIMAB/IMDEVIMAB
por: TOOR, SUBHAN A, et al.
Publicado: (2022)

Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19
por: Markovitz, Netana H., et al.
Publicado: (2022)

Dégradation respiratoire post Casirivimab/Imdevimab : fréquence et facteurs de risque
por: Gerber, V., et al.
Publicado: (2022)

Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV)
por: Singh, Gurdeep, et al.
Publicado: (2022)

A SEVERE ADVERSE DRUG REACTION (ADR) TO REGEN-COV (CASIRIVIMAB AND IMDEVIMAB)
por: Abou-Jaoude, E., et al.
Publicado: (2022)

Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors
por: Yoshida, Junichi, et al.
Publicado: (2022)

Risk factors for progression to acute respiratory failure after casirivimab and imdevimab administration: A retrospective study
por: Ito, Noriaki, et al.
Publicado: (2022)

Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
por: Phan, Alexander T, et al.
Publicado: (2021)

506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis
por: Chundi, Vahini, et al.
Publicado: (2021)

1144. Rate of Infusion Reactions Among Patients Receiving Casirivimab/Imdevimab in the Home Setting
por: Simpson, Michelle, et al.
Publicado: (2022)

French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)

Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan
por: Terakawa, Kanako, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6l39l286ao20t7bigguhr8kegt